Shares of Allergan lost one percent on Monday, making it TheStreet's move of the day. The drugmaker rejected Valeant Pharmaceuticals International's $47 billion takeover bid, calling its rival's business model unsustainable and saying that too much uncertainty remains about Valeant's long-term outlook. Allergan said in a letter to Valeant CEO Michael Peterson on Monday, "[Your] Proposal includes a large stock component, which we believe is a risk for Allergan stockholders due to the uncertainty surrounding Valeant's long term growth prospects and business model." TheStreet's Joe Deaux breaks down the move from New York.

More from Video

Video: This One Mathematical Concept Can Make You a Millionaire

Video: This One Mathematical Concept Can Make You a Millionaire

AAP Exclusive: Nvidia is Tied to Crypto and That's Bad

AAP Exclusive: Nvidia is Tied to Crypto and That's Bad

Video: Abercrombie & Fitch Shares Surged 57% So Far This Year

Video: Abercrombie & Fitch Shares Surged 57% So Far This Year

Video: Why It's Key to Invest in Stocks Even If You Have Student Loan Debt

Video: Why It's Key to Invest in Stocks Even If You Have Student Loan Debt

Video: The S&P 500 Is Failing to Make New Highs

Video: The S&P 500 Is Failing to Make New Highs